CDT Equity (NASDAQ:CDT) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of CDT Equity (NASDAQ:CDT) from a strong sell rating to a sell rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

CDT Equity Stock Up 9.3%

CDT stock opened at $2.93 on Friday. CDT Equity has a 12 month low of $2.53 and a 12 month high of $3,800.00. The firm has a market cap of $1.44 million, a P/E ratio of -0.00 and a beta of 1.49. The company’s 50-day moving average price is $6.33 and its two-hundred day moving average price is $97.95.

CDT Equity (NASDAQ:CDT) last issued its earnings results on Wednesday, July 15th. The company reported ($55.60) EPS for the quarter.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.